Wikidata

(Q44616783)

English

Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: results of a large, multicentre phase II study.

scientific article published on 14 October 2003

In more languages
default for all languages
No label defined

No description defined

Statements

title
Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: results of a large, multicentre phase II study (English)
1 reference
stated in
Europe PubMed Central
PubMed publication ID
14557896
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14557896%20AND%20SRC:MED&resulttype=core&format=json
retrieved
20 December 2019
author name string

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    Retrieved from "https://www.wikidata.org/w/index.php?title=Q44616783&oldid=2206793615"